Abstract
High-level production (880 mg liter(-1)) and isolation of the anteiso-C(17) isoform of the lipopeptide mycosubtilin produced by a genetically engineered Bacillus subtilis strain are reported. Antifungal activity of this isoform, as determined via culture and fluorometric and cell leakage assays, suggests its potential therapeutic use as an antifungal agent, in particular against Candida spp.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antifungal Agents / biosynthesis*
-
Bacillus subtilis / genetics
-
Bacillus subtilis / metabolism*
-
Biosynthetic Pathways / genetics
-
Candida / drug effects*
-
Genes, Bacterial
-
Genetic Engineering
-
Lipoproteins / biosynthesis
-
Microbial Sensitivity Tests
-
Protein Isoforms / metabolism
Substances
-
Antifungal Agents
-
Lipoproteins
-
Protein Isoforms
-
mycosubtiline